Literature DB >> 3157529

HLA antigens and adverse drug reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.

S R Dahlqvist, H Ström, A Bjelle, E Möller.   

Abstract

The association between HLA antigens and adverse drug reactions (ADR), (e.g. proteinuria, haematological abnormalities, stomatitis, diarrhoea and dermatitis) in rheumatoid arthritis (RA) to sodium aurothiomalate (gold) and to D-penicillamine (PA) were studied in 32 patients. Thirty-eight RA patients treated with gold and PA, and with no ADR to these drugs, were used as controls. The frequency of HLA B8 was significantly (p less than 0.05) increased among RA patients with ADR compared to plasma donors. DR3 was also significantly increased (p less than 0.05) in RA patients with haematological ADR compared to plasma donors. Haematological ADR occurred significantly (p less than 0.05) more often in DR3 positive patients (55%) than among DR3 negative RA patients (27%).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157529     DOI: 10.1007/bf02032318

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Nephropathy induced by D-penicillamine.

Authors:  I A Jaffe; G Treser; Y Suzuki; T Ehrenreich
Journal:  Ann Intern Med       Date:  1968-09       Impact factor: 25.391

2.  The lymphocyte transformation test and gold hypersensitivity.

Authors:  E J Denman; A M Denman
Journal:  Ann Rheum Dis       Date:  1968-11       Impact factor: 19.103

3.  Gold-induced hepatotoxicity: case report and review of the literature.

Authors:  D L Howrie; J C Gartner
Journal:  J Rheumatol       Date:  1982 Sep-Oct       Impact factor: 4.666

4.  Agranulocytosis, levamisole, and HLA-B27.

Authors:  K L Schmidt; C Mueller-Eckhardt
Journal:  Lancet       Date:  1977-07-09       Impact factor: 79.321

5.  Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy.

Authors:  R Luukkainen
Journal:  Scand J Rheumatol Suppl       Date:  1980

6.  Agranulocytosis, levamisole, and HLA-B27.

Authors:  E M Veys; H Mielants; M Rosenthal
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321

7.  HLA B27 in the population of northern Sweden.

Authors:  A Bjelle; B Cedergren; S R Dahlqvist
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

8.  Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.

Authors:  J S Coblyn; M Weinblatt; D Holdsworth; D Glass
Journal:  Ann Intern Med       Date:  1981-08       Impact factor: 25.391

9.  Association of HLA-DRw4 with rheumatoid arthritis in black and white patients.

Authors:  R W Karr; G E Rodey; T Lee; B D Schwartz
Journal:  Arthritis Rheum       Date:  1980-11

10.  HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P H Wooley; J Griffin; G S Panayi; J R Batchelor; K I Welsh; T J Gibson
Journal:  N Engl J Med       Date:  1980-08-07       Impact factor: 91.245

View more
  3 in total

1.  Association of HLA-B35 with mucocutaneous lesions in Israeli patients with rheumatoid arthritis receiving gold treatment.

Authors:  M Tishler; D Caspi; E Gazit; M Yaron
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

2.  HLA-DR antigens in rheumatoid arthritis. A Swiss collaborative study; final report. Swiss Federal Commission for the Rheumatic Diseases, Subcommission for Research.

Authors: 
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

Review 3.  Drug-induced immune thrombocytopenia.

Authors:  Patricia M L A van den Bemt; Ronald H B Meyboom; Antoine C G Egberts
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.